Microbiota Therapy
Fecal Microbiota Transplant for Hidradenitis Suppurativa
This trial looks into a new treatment for HS with only one FDA-approved option. It hopes to investigate if gut microbiome changes can improve HS, which significantly reduces quality of life & has high medical costs.
Monoclonal Antibodies
Eltrekibart for Hidradenitis Suppurativa
This trial is testing a new medication called eltrekibart to find the most effective treatment for adults with moderate-to-severe hidradenitis suppurativa. The goal is to see if it can safely and effectively reduce symptoms by targeting inflammation pathways.
Popular Filters
Trials for HS Patients
Temporizing Matrix
BTM vs Human Cadaveric Allograft for Hidradenitis Suppurativa
This trial compares a new wound treatment with standard methods in patients with Hidradenitis suppurativa. The new treatment helps wounds heal by providing a temporary structure for new tissue growth, while standard methods use traditional wound care techniques. The new treatment has shown positive outcomes in healing burns and plastic surgery wounds, but its effectiveness in diabetic foot wounds has not yet been established.
Monoclonal Antibodies
Lutikizumab for Hidradenitis Suppurativa
This trial is testing a new drug called lutikizumab to help adults with a painful skin condition called hidradenitis suppurativa (HS) who haven't been helped by other treatments. The drug works by reducing inflammation in the skin.
Monoclonal Antibodies
Bimekizumab for Hidradenitis Suppurativa
This trial is testing the safety of bimekizumab, a medication for people with moderate to severe hidradenitis suppurativa (HS). Bimekizumab aims to reduce inflammation and alleviate symptoms by targeting certain proteins in the body.
Phase 3 Trials
Monoclonal Antibodies
Bimekizumab for Hidradenitis Suppurativa
This trial is testing the safety of bimekizumab, a medication for people with moderate to severe hidradenitis suppurativa (HS). Bimekizumab aims to reduce inflammation and alleviate symptoms by targeting certain proteins in the body.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Hidradenitis Suppurativa
This trial is testing if a daily pill called upadacitinib can help people with a painful skin condition called hidradenitis suppurativa (HS) who haven't responded to usual treatments. The study will involve adults and teenagers and will check for safety and effectiveness over time. Participants will be randomly given either the medication or a non-active pill, and their progress will be monitored through periodic medical check-ups.
Monoclonal Antibodies
Spesolimab for Hidradenitis Suppurativa
This trial tests spesolimab, a drug that may help adults with moderate to severe hidradenitis suppurativa (HS). It works by calming the immune system to reduce inflammation and heal the skin. The study aims to see if spesolimab is effective and safe for these patients.
Trials With No Placebo
Temporizing Matrix
BTM vs Human Cadaveric Allograft for Hidradenitis Suppurativa
This trial compares a new wound treatment with standard methods in patients with Hidradenitis suppurativa. The new treatment helps wounds heal by providing a temporary structure for new tissue growth, while standard methods use traditional wound care techniques. The new treatment has shown positive outcomes in healing burns and plastic surgery wounds, but its effectiveness in diabetic foot wounds has not yet been established.
Monoclonal Antibodies
Bimekizumab for Hidradenitis Suppurativa
This trial is testing the safety of bimekizumab, a medication for people with moderate to severe hidradenitis suppurativa (HS). Bimekizumab aims to reduce inflammation and alleviate symptoms by targeting certain proteins in the body.
Janus Kinase (JAK) Inhibitor
Topical Ruxolitinib Cream for Hidradenitis Suppurativa
This trial is testing whether a cream containing the drug ruxolitinib can reduce disease activity in people with HS. Investigators will also study how this drug affects inflammation by looking at skin biopsy samples.
Frequently Asked Questions
Introduction to hidradenitis suppurativa
What are the top hospitals conducting hidradenitis suppurativa research?
Hidradenitis suppurativa, a chronic inflammatory skin condition, has presented challenges for both patients and healthcare providers alike. However, several hospitals across the United States are leading the charge in seeking innovative solutions through clinical trials. In Miami, the University of Miami is making strides with three ongoing hidradenitis suppurativa trials and a total of five conducted thus far. This institution recently recorded its first trial focused on this condition in 2020. Meanwhile, Beth Israel Deaconess Medical Center in Boston is also actively involved with two ongoing trials and has an impressive history of eight completed studies since initiating their initial investigation in 2016.
Further contributing to advancements in hidradenitis suppurativa research are Progressive Clinical Research in San Antonio and Clinical Research Site locations in Encino and Los Angeles. Each site currently engages two active clinical trials for this condition while having conducted prior investigations as well. These sites have made valuable contributions to understanding hidradenitis suppurativa since recording their first respective trials between 2018-2022.
These hospitals represent beacons of hope for individuals living with hidradenitis suppurativa by providing access to cutting-edge treatments through clinical trials that aim to improve quality of life. With each new study undertaken at these renowned institutions, we move closer towards alleviating the burden faced by those affected by this challenging skin condition that affects millions worldwide.
Which are the best cities for hidradenitis suppurativa clinical trials?
When it comes to hidradenitis suppurativa clinical trials, several cities have emerged as prominent locations for research and development. Tampa, Florida leads the way with 15 active trials exploring treatments like Upadacitinib Dose A and INCB054707. Indianapolis, Indiana follows closely behind with 8 ongoing studies focusing on Upadacitinib Dose A and Izokibep among others. Los Angeles, California also offers a strong presence in the field with 8 active trials investigating therapies such as Upadacitinib Dose A, Izokibep, and Bimekizumab. These cities provide individuals suffering from hidradenitis suppurativa access to cutting-edge clinical trials that aim to improve treatment options and ultimately enhance patient outcomes.
Which are the top treatments for hidradenitis suppurativa being explored in clinical trials?
In the realm of hidradenitis suppurativa, one treatment stands out in current clinical trials - SAR442970. Although still in its early stages with one active trial, this innovative therapy shows promise for addressing the challenges posed by this condition. First listed in 2023, SAR442970 is a beacon of hope as researchers delve deeper into exploring effective treatments for hidradenitis suppurativa.
What are the most recent clinical trials for hidradenitis suppurativa?
Promising advancements in the field of hidradenitis suppurativa are emerging through recent clinical trials, offering hope to those affected by this challenging condition. One such trial is investigating the effectiveness of SAR442970, a novel treatment for hidradenitis suppurativa currently in Phase 2. Another study focuses on Group 2: Izokibep subcutaneous once weekly, which has entered Phase 3 and shows potential as a therapeutic option. Additionally, ongoing research explores the benefits of Upadacitinib Dose A in patients with hidradenitis suppurativa during its Phase 3 stage. These trials highlight the dedication of scientists and healthcare professionals working towards improving outcomes for individuals living with hidradenitis suppurativa.
What hidradenitis suppurativa clinical trials were recently completed?
Numerous recent clinical trials have been completed to advance the treatment of hidradenitis suppurativa. Notably, Aclaris Therapeutics conducted a trial for ATI-450 in December 2021, while Rockefeller University concluded their study on Brodalumab in August 2021. In July 2021, AnaptysBio wrapped up a trial investigating Imsidolimab, followed by Boehringer Ingelheim's completion of their Spesolimab trial in April 2021. Kymera Therapeutics made progress with their KT-474 study in February 2021 and Eli Lilly and Company completed a trial for LY3041658 in August 2020. These endeavors signify significant steps towards finding improved therapies for individuals living with hidradenitis suppurativa.